Four compounds entering "advanced" clinicals are the anti- virals famciclovir/penciclovir for genital herpes and herpes zoster infection in immune-compromised patients; ropinirole for Parkinson's disease; topotecan as a treatment for solid tumors; and SK&F 105657 for benign prostatic hypertrophy, company notes in its recently-released annual report for 1991. SB says these are the "leading candidates" among 10 or more new products it "is committed to filing in our major markets over the next five years".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth